Evidence map›Paper›PMID 41588207›Full record

SynthesisEuropean journal of nuclear medicine and molecular imaging2026

Predicting the unpredictable: prognostic and predictive power of FAPI-PET imaging in oncology: a systematic review and meta-analysis.

Sajjad Sadeghpour, Atena Aghaee, Saba Sadeghpour, Alessio Rizzo, Daniele Antonio Pizzuto, Salvatore Annunziata, Giorgio Treglia, Ramin Sadeghi

Abstract readSystematic ReviewMeta-AnalysisReview
PubMed Publisher
In one paragraph

Synthesis in European journal of nuclear medicine and molecular imaging, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Sajjad SadeghpourNuclear Medicine Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.
Atena AghaeeNuclear Medicine Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.
Saba SadeghpourMadani Hospital, Gonabad University of Medical Sciences, Gonabad, Iran.
Alessio RizzoDepartment of Nuclear Medicine, Candiolo Cancer Institute, Torino, Italy.
Daniele Antonio PizzutoNuclear Medicine Unit, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy.
Salvatore AnnunziataNuclear Medicine Unit, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy.
Giorgio TregliaDivision of Nuclear Medicine, Ente Ospedaliero Cantonale, Bellinzona, CH-6500, Switzerland. giorgiomednuc@libero.it.ORCID 0000-0001-9808-780X
Ramin SadeghiNuclear Medicine Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesIn this systematic review, we evaluated the accuracy of baseline fibroblast activation protein inhibitor (FAPI)-based PET scans for predicting overall survival (OS), progression-free survival (PFS), and tumor response after treatment completion.

methodsWe searched PubMed and Cochrane Library until August 2025 to identify studies that evaluated the prognostic and predictive value of FAPI-based PET scans parameters in the OS, PFS, and treatment response of cancer patients; all studies reporting these findings, whether as the main or a secondary finding, were included.

resultsOf the forty-seven publications, including 1430 patients, various cancer types from breast to pancreatic cancer, were evaluated. The pooled hazard ratio (HR) indicated that patients with higher maximum standardized uptake value (SUVmax) were significantly associated with poor OS (HR: 2.36; 95% CI: 1.56-3.56, p < 0.011) and poor PFS (HR: 1.88; 95% CI: 1.36-2.60, p < 0.001). Patients with higher FAPI-avid tumor volume (MTV) were significantly associated with poorer OS (HR: 3.33; 95% CI: 1.99-5.56, p < 0.001) and PFS (HR: 2.42; 95% CI: 1.60-3.67, p < 0.001). High total lesion FAP expression (TLFAPI) was significantly associated with poorer OS (HR: 3.35; 95% CI: 2.05-5.50, p < 0.001) and PFS (HR: 2.45, 95% CI: 1.61-3.73, p < 0.001).

conclusionEarly evidence indicates that FAPI PET parameters, especially the baseline of MTV, SUVmax, and TLFAPI, can be proper prognostic markers of OS and PFS in cancers by imaging tumor stroma. In various cancers, FAPI uptake parameters change after treatment, or baseline levels are linked to treatment outcomes.

Indexed as

NeoplasmsPositron-Emission TomographyFibroblast Activation Protein AlphaHumansPrognosisFibroblast Activation Protein AlphaCancerFAPIPETPrognosisSurvivalTreatment response

Identifiers

PMID41588207

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.